Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease

Author： Jenner Peter  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.6, 2005-06, pp. : 729-738

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations

By Müller Thomas  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1015-1024

Informa Healthcare

Access to resources Recommend Favorite

Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant

By Perez-Lloret Santiago   Merello Marcelo  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 8, 2014-06 ,pp. : 1097-1107

Informa Healthcare

Access to resources Recommend Favorite

Istradefylline for the treatment of Parkinson's disease

By Park Ariane   Stacy Mark  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 1, 2012-01 ,pp. : 111-114

Informa Healthcare

Access to resources Recommend Favorite

Adenosine A2A Receptor Antagonists for Parkinson’s Disease: Rationale, Therapeutic Potential and Clinical Experience

By Hauser Robert A.  

Drugs & Aging, Vol. 22, Iss. 6, 2005-01 ,pp. : 471-482

Adis International

Access to resources Recommend Favorite

Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists

By Szabóó Nikoletta   Kincses Zsigmond Tamáás   Véécsei Láászlóó  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 4, 2011-04 ,pp. : 441-455

Informa Healthcare

Access to resources Recommend Favorite